Table 2.

Demographic and histopathologic characteristics of the exploratory cohort A

		All patients (n = 23)	Seizure patients (n = 12)	Seizure-free patients (n = 11)	p value (seizure vs. non-seizure)
Age	years	51.9 ± 11.9	47.1 ± 8.4	57.1 ± 13.2	0.040
Sex	female	3 (13.0%)	2 (16.7%)	1 (9.1%)	1.000
Diagnosis	Glioblastoma, IDH-wildtype	11 (47.8%)	4 (33.3%)	7 (63.6%)	0.103
	Astrocytoma, IDH-mutant	5 (21.7%)	2 (16.7%)	3 (27.3%)
	Oligodendroglioma, IDH-mutant & 1p/19q-codeleted	7 (30.4%)	6 (50.0%)	1 (9.1%)
CNS WHO grade	4	12 (52.2%)	4 (33.3%)	8 (72.7%)	0.125
	3	6 (26.1%)	5 (41.7%)	1 (9.1%)
	2	5 (21.7%)	3 (25.0%)	2 (18.2)
IDH-1 status	mutated	12 (52.2%)	8 (66.7%)	4 (36.4%)	0.220
1p19q status	codeleted	7 (30.4%)	6 (50.0%)	1 (9.1%)	0.069
	wildtype or missing	16 (69.6%)	6 (50.0%)	10 (90.9%)
MGMT status	methylated	17 (73.9%)	9 (75.0%)	8 (72.7%)	1.000
	unmethylated or missing	4 (17.4%)	2 (16.7%)	2 (18.2%)
	N/A	2 (8.7%)	1 (8.3%)	1 (9.1%)
Localization	frontal	9 (39.1%)	5 (41.7%)	4 (36.4%)	0.750
	parietal	6 (26.1%)	3 (25.0%)	3 (27.3%)
	temporal	7 (30.4%)	3 (25.0%)	4 (36.4%)
	occipital	1 (4.3%)	1 (8.3%)	0 (0.0%)
Edema volume	cm³	41.6 ± 44.8	33.0 ± 35.6	51.0 ± 53.2	0.268